# Efficacy, Safety and Pharmacokinetics of BCD-100 (Anti-PD-1) Monotherapy as Second Line Treatment in Patients With Non-Small Cell Lung Cancer (DOMINUS)

> **NCT03288870** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Biocad** · enrollment: 218 (estimated)

## Conditions studied

- Non Small Cell Lung Cancer Stage IIIB
- Non-Small Cell Carcinoma of Lung, TNM Stage 4

## Interventions

- **DRUG:** BCD-100
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT03288870
- **Lead sponsor:** Biocad
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-09-19
- **Primary completion:** 2020-08-10
- **Final completion:** 2021-08-10
- **Target enrollment:** 218 (ESTIMATED)
- **Last updated:** 2020-10-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03288870

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03288870, "Efficacy, Safety and Pharmacokinetics of BCD-100 (Anti-PD-1) Monotherapy as Second Line Treatment in Patients With Non-Small Cell Lung Cancer (DOMINUS)". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03288870. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*